AI Article Synopsis
- Immunotherapy is a promising treatment for malignant gliomas, allowing targeted attack on cancer cells with less risk of harming normal brain tissue.
- Current vaccine therapies are undergoing clinical trials and showing positive results, but new methods for monitoring immune responses are needed to evaluate their effectiveness due to the challenges posed by inflammation.
- Enhancing immunomonitoring techniques could improve research on therapeutic options and better assess the effectiveness of existing treatments for gliomas.
Article Abstract
Immunotherapy provides the ideal candidate of therapeutic attack against malignant gliomas because it allows for targeting of cancer cells without the potential for nonspecific toxicity. This is important when glial tumor cells spread far through normal brain tissue. Current vaccine therapies are in clinical trials and are showing beneficial responses. Given that the inflammatory response may make serial radiographic imaging more difficult to interpret, newer methodologies of immunomonitoring must be developed to assess the biologic efficacy of these immunotherapies. This article reviews methods of monitoring the immune system after vaccination against malignant gliomas. Improvements in immunomonitoring should lead to an increase in the efficiency of identifying viable avenues of therapeutic research, and assess the efficacy of those currently employed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.nec.2009.09.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!